Literature DB >> 10680011

Lentiviral vectors: turning a deadly foe into a therapeutic agent.

D Trono1.   

Abstract

The past 3 years have witnessed the spectacular irruption of lentiviral vectors into the limelight of the gene therapy scene. Owing to their ability to deliver transgenes in tissues that had long appeared irremediably refractory to stable genetic manipulation, lentivectors have opened fresh perspectives for the genetic treatment of a wide array of hereditary as well as acquired disorders, and a concrete proposal for their clinical use seems imminent. This article traces the path that has led to this rapid development and describes the current state of the art in the design and production of lentiviral vectors. The important question of biosafety is discussed. This system seems to have the edge over other gene delivery tools for particular targets, however, there remain several issues to be resolved before lentivectors make it to the bedside. Gene Therapy (2000) 7, 20-23.

Mesh:

Year:  2000        PMID: 10680011     DOI: 10.1038/sj.gt.3301105

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  38 in total

1.  Gene therapy: new "magic bullets" to prevent ocular scarring.

Authors:  P T Khaw; A D Cambrey; G A Limb; J T Daniels
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

2.  Optimization of magnetic nanoparticle-assisted lentiviral gene transfer.

Authors:  Christina Trueck; Katrin Zimmermann; Olga Mykhaylyk; Martina Anton; Sarah Vosen; Daniela Wenzel; Bernd K Fleischmann; Alexander Pfeifer
Journal:  Pharm Res       Date:  2012-01-25       Impact factor: 4.200

3.  Lentivirus-based genetic manipulations of cortical neurons and their optical and electrophysiological monitoring in vivo.

Authors:  Tanjew Dittgen; Axel Nimmerjahn; Shoji Komai; Pawel Licznerski; Jack Waters; Troy W Margrie; Fritjof Helmchen; Winfried Denk; Michael Brecht; Pavel Osten
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-17       Impact factor: 11.205

4.  Analysis of post-transcriptional regulations by a functional, integrated, and quantitative method.

Authors:  Benoît Laloo; Delphine Simon; Véronique Veillat; Dorine Lauzel; Véronique Guyonnet-Duperat; François Moreau-Gaudry; Francis Sagliocco; Christophe Grosset
Journal:  Mol Cell Proteomics       Date:  2009-08       Impact factor: 5.911

5.  Unaltered repopulation properties of mouse hematopoietic stem cells transduced with lentiviral vectors.

Authors:  Africa Gonzalez-Murillo; M Luz Lozano; Eugenio Montini; Juan A Bueren; Guillermo Guenechea
Journal:  Blood       Date:  2008-08-06       Impact factor: 22.113

Review 6.  Recent advances in lentiviral vector development and applications.

Authors:  Janka Mátrai; Marinee K L Chuah; Thierry VandenDriessche
Journal:  Mol Ther       Date:  2010-01-19       Impact factor: 11.454

7.  Sustained, localized transgene expression mediated from lentivirus-loaded biodegradable polyester elastomers.

Authors:  Michele C Jen; Kevin Baler; Ashleigh R Hood; Seungjin Shin; Lonnie D Shea; Guillermo A Ameer
Journal:  J Biomed Mater Res A       Date:  2012-10-15       Impact factor: 4.396

8.  Separating lentiviral vector injection and induction of gene expression in time, does not prevent an immune response to rtTA in rats.

Authors:  David M Markusic; Dirk R de Waart; Jurgen Seppen
Journal:  PLoS One       Date:  2010-04-01       Impact factor: 3.240

9.  Heterologous human immunodeficiency virus type 1 lentiviral vectors packaging a simian immunodeficiency virus-derived genome display a specific postentry transduction defect in dendritic cells.

Authors:  Caroline Goujon; Loraine Jarrosson-Wuilleme; Jeanine Bernaud; Dominique Rigal; Jean-Luc Darlix; Andrea Cimarelli
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  Reduction of liver macrophage transduction by pseudotyping lentiviral vectors with a fusion envelope from Autographa californica GP64 and Sendai virus F2 domain.

Authors:  David M Markusic; Niek P van Til; Johan K Hiralall; Ronald P J Oude Elferink; Jurgen Seppen
Journal:  BMC Biotechnol       Date:  2009-10-07       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.